Recent research has demonstrated that inhibition of intestinal FXR signaling can improve metabolic disorders by increasing hepatic bile acid pool, reducing cholesterol accumulation, and alleviating fatty liver (147). This evidence concerns the gene NR1H4 and metabolic disease.